Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Medicare and Medicaid
CMS Decision - No Material Financial Impact to Medicsight
June 28th, 2009
Medicsight PLC, a subsidiary of MGT Capital Investments, Inc. (NYSE Amex: MGT) and an industry leader in the development of Computer-Aided Detection (CAD) and image analysis software, which assists radiologists in the early detection of disease, comments on the Centers for Medicare and Medicaid Services' (CMS) decision not to reimburse virtual colonoscopy (CT colonography or CTC) for the routine colon cancer screening of Medicare patients in the U.S. The CMS decision has no material financial impact to Medicsight and only affects 12% of the eligible screening population in the United States. CTC continues to be reimbursed by Medicare for diagnostic procedures under...
Source: Pharma Investments, Ventures & Law Weekly (2009-06-28)
|
